Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Jan O. Aasly 2 Articles
Increased Mortality in Young-Onset Parkinson’s Disease
Eldbjørg Hustad, Tor Åge Myklebust, Sasha Gulati, Jan O. Aasly
J Mov Disord. 2021;14(3):214-220.   Published online July 29, 2021
DOI: https://doi.org/10.14802/jmd.21029
  • 22,037 View
  • 318 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Objective
Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease onset (AAO) and cognitive decline defined as Montreal Cognitive Assessment (MoCA) score below 26.
Methods
The cohort was followed longitudinally from 1997. By the end of January 2020, 587 patients had died. Comparisons to the Norwegian population were performed by calculating standardized mortality ratios (SMRs). Survival curves were estimated using the standard Kaplan-Meier estimator, and multivariable Cox proportional hazard models were estimated to investigate associations.
Results
SMR was 2.28 [95% confidence interval (CI): 2.13–2.44] for the whole cohort. For participants with AAO 20–39 years, the SMR was 5.55 (95% CI: 3.38–8.61). Median survival was 15 years (95% CI: 14.2–15.5) for the whole cohort. Early-onset PD (EOPD) patients (AAO < 50 years) had the longest median survival time. For all groups, there was a significant shortening in median survival time and an almost 3-fold higher age- and sex-adjusted hazard ratio for death when the MoCA score decreased below 26.
Conclusion
PD patients with an AAO before 40 years had a more than fivefold higher mortality rate compared to a similar general population. EOPD patients had the longest median survival; however, their life expectancy was reduced to a greater degree than that of late-onset PD patients. Cognitive impairment was strongly associated with mortality in PD.

Citations

Citations to this article as recorded by  
  • Case‐Fatality Rate in Parkinson's Disease: A Nationwide Registry Study
    Jussi O.T. Sipilä, Valtteri Kaasinen, Päivi Rautava, Ville Kytö
    Movement Disorders Clinical Practice.2024; 11(2): 152.     CrossRef
  • Tinetti balance performance is associated with mortality in older adults with late-onset Parkinson’s disease: a longitudinal study
    Louise Laurent, Pierre Koskas, Janina Estrada, Mélanie Sebbagh, Sophie Lacaille, Agathe Raynaud-Simon, Matthieu Lilamand
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Letter in response to Cole-Hunter et al., 2023: What does “Parkinson’s disease mortality” mean?
    Isabell Katharina Rumrich, Valtteri Kaasinen, Otto Hänninen, Sirpa Hartikainen, Anna-Maija Tolppanen
    Environment International.2023; 173: 107852.     CrossRef
  • Differences in Survival across Monogenic Forms of Parkinson's Disease
    Aymeric Lanore, Fanny Casse, Christelle Tesson, Thomas Courtin, Poornima Jayadev Menon, Sara Sambin, Graziella Mangone, Louise‐Laure Mariani, Suzanne Lesage, Alexis Brice, Alexis Elbaz, Jean‐Christophe Corvol
    Annals of Neurology.2023; 94(1): 123.     CrossRef
  • Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019
    Xiao-qin Liu, Xiao-yu Wang, Hui-ming Shen, Wen-yuan Pang, Ming-kang Zhong, Chun-lai Ma
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Montreal cognitive assessment (MoCA) is highly correlated with 1-year mortality in hip fracture patients
    R. M. Y. Wong, R. W. K. Ng, W. W. Chau, W. H. Liu, S. K. H. Chow, C. Y. Tso, N. Tang, W.-H. Cheung
    Osteoporosis International.2022; 33(10): 2185.     CrossRef
  • Obituary for Jan O. Aasly (1950–2022)
    Matthew J. Farrer
    Movement Disorders.2022; 37(9): 1783.     CrossRef
  • Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease
    Raja Mehanna, Katarzyna Smilowska, Jori Fleisher, Bart Post, Taku Hatano, Maria Elisa Pimentel Piemonte, Kishore Raj Kumar, Victor McConvey, Baorong Zhang, Eng‐King Tan, Rodolfo Savica
    Movement Disorders Clinical Practice.2022; 9(7): 869.     CrossRef
Long-Term Outcomes of Genetic Parkinson’s Disease
Jan O. Aasly
J Mov Disord. 2020;13(2):81-96.   Published online May 29, 2020
DOI: https://doi.org/10.14802/jmd.19080
  • 13,735 View
  • 423 Download
  • 20 Web of Science
  • 22 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 1–2% of people by the age of 70 years. Age is the most important risk factor, and most cases are sporadic without any known environmental or genetic causes. Since the late 1990s, mutations in the genes SNCA, PRKN, LRRK2, PINK1, DJ-1, VPS35, and GBA have been shown to be important risk factors for PD. In addition, common variants with small effect sizes are now recognized to modulate the risk for PD. Most studies in genetic PD have focused on finding new genes, but few have studied the long-term outcome of patients with the specific genetic PD forms. Patients with known genetic PD have now been followed for more than 20 years, and we see that they may have distinct and different prognoses. New therapeutic possibilities are emerging based on the genetic cause underlying the disease. Future medication may be based on the pathophysiology individualized to the patient’s genetic background. The challenge is to find the biological consequences of different genetic variants. In this review, the clinical patterns and long-term prognoses of the most common genetic PD variants are presented.

Citations

Citations to this article as recorded by  
  • Navigating the Frontiers of Machine Learning in Neurodegenerative Disease Therapeutics
    Yoonjeong Cha, Mohamedi N. Kagalwala, Jermaine Ross
    Pharmaceuticals.2024; 17(2): 158.     CrossRef
  • The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art
    Júlio César Claudino dos Santos, Gabriela Braga Cabrera Mano, André Rodrigues da Cunha Barreto-Vianna, Tulia Fernanda Meira Garcia, Aline Vieira de Vasconcelos, Caio Sérgio Gomes Sá, Sarah Lopes de Souza Santana, Ana Gabriela Ponte Farias, Beatriz Seimaru
    Molecular Neurobiology.2024;[Epub]     CrossRef
  • Early Onset Parkinson’s Disease and It’s Genetic Consequences
    Hatice ÖMERCİKOĞLU ÖZDEN, Dilek GÜNAL
    OSMANGAZİ JOURNAL OF MEDICINE.2024;[Epub]     CrossRef
  • Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
    Poornima Jayadev Menon, Sara Sambin, Baptiste Criniere-Boizet, Thomas Courtin, Christelle Tesson, Fanny Casse, Melanie Ferrien, Louise-Laure Mariani, Stephanie Carvalho, Francois-Xavier Lejeune, Sana Rebbah, Gaspard Martet, Marion Houot, Aymeric Lanore, G
    npj Parkinson's Disease.2024;[Epub]     CrossRef
  • Factors Influencing Patient Disclosure of Parkinson's Disease Genetic Testing Results to Relatives
    Jeanine Schulze, Jasmine Kaur Dhaliwal, Mandy Miller, Emily Quinn, Leah Wetherill, Lola Cook
    Movement Disorders Clinical Practice.2024;[Epub]     CrossRef
  • Disparities in Access to Deep Brain Stimulation for Parkinson’s Disease and Proposed Interventions: A Literature Review
    Anthony E. Bishay, Natasha C. Hughes, Michael Zargari, Danika L. Paulo, Steven Bishay, Alexander T. Lyons, Mariam N. Morkos, Tyler J. Ball, Dario J. Englot, Sarah K. Bick
    Stereotactic and Functional Neurosurgery.2024; : 1.     CrossRef
  • Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life
    Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Maria Cristina Íñiguez-Alvarado, Iago García Díaz, Silvia Jesús, Maria Teresa Buongiorno, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caball
    Journal of Parkinson's Disease.2023; 13(3): 379.     CrossRef
  • To lump or to split? Deep brain stimulation may improve non-motor symptoms in certain Parkinson's disease subtypes
    Neepa Patel
    Parkinsonism & Related Disorders.2023; 109: 105369.     CrossRef
  • Emerging Roles of Signal Transduction Pathways in Neurodegenerative Diseases. Hunting New Possible Therapeutic Molecular Targets
    Vincenza Rita Lo Vasco
    OBM Geriatrics.2023; 07(02): 1.     CrossRef
  • Genome- and Exome-Wide Association Studies Revealed Candidate Genes Associated with DaTscan Imaging Features
    Arash Yaghoobi, Homa Seyedmirzaei, Moein Ala, Cristine Alves da Costa
    Parkinson's Disease.2023; 2023: 1.     CrossRef
  • Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
    Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
    Brain Sciences.2023; 13(10): 1471.     CrossRef
  • Applicability of clinical genetic testing for deep brain stimulation treatment in monogenic Parkinson’s disease and monogenic dystonia: a multidisciplinary team perspective
    Valentino Rački, Mario Hero, Eliša Papić, Gloria Rožmarić, Nada Starčević Čizmarević, Darko Chudy, Borut Peterlin, Vladimira Vuletić
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy
    Tinh Thi Nguyen, Yun Joong Kim, Thuy Thi Lai, Phuong Thi Nguyen, Young Ho Koh, Linh Thi Nhat Nguyen, Hyeo-il Ma, Young Eun Kim
    Journal of Parkinson's Disease.2022; 12(4): 1201.     CrossRef
  • Oncogenic Pathways in Neurodegenerative Diseases
    Luis Varela, Maria E. R. Garcia-Rendueles
    International Journal of Molecular Sciences.2022; 23(6): 3223.     CrossRef
  • Genetic Determinants of Survival in Parkinson's Disease in the Asian Population
    Chunyu Li, Yanbing Hou, Ruwei Ou, Xiaojing Gu, Yongping Chen, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Bei Cao, Qianqian Wei, Xueping Chen, Wei Song, Bi Zhao, Ying Wu, Yiyuan Cui, Huifang Shang
    Movement Disorders.2022; 37(8): 1624.     CrossRef
  • Obituary for Jan O. Aasly (1950–2022)
    Matthew J. Farrer
    Movement Disorders.2022; 37(9): 1783.     CrossRef
  • Genetics in parkinson’s disease: From better disease understanding to machine learning based precision medicine
    Mohamed Aborageh, Peter Krawitz, Holger Fröhlich
    Frontiers in Molecular Medicine.2022;[Epub]     CrossRef
  • Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies
    Shivam Kumar Pandey, Rakesh Kumar Singh
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study
    Daniel Weiss, Zied Landoulsi, Patrick May, Manu Sharma, Michael Schüpbach, Hana You, Jean Christophe Corvol, Steffen Paschen, Ann-Kristin Helmers, Michael Barbe, Gereon Fink, Andrea A. Kühn, Christine Brefel Courbon, Lars Wojtecki, Philippe Damier, Valeri
    Parkinsonism & Related Disorders.2022; 103: 169.     CrossRef
  • Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort
    Jan O. Aasly
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Increased Mortality in Young-Onset Parkinson’s Disease
    Eldbjørg Hustad, Tor Åge Myklebust, Sasha Gulati, Jan O. Aasly
    Journal of Movement Disorders.2021; 14(3): 214.     CrossRef
  • Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort
    Sylvia Binck, Claire Pauly, Michel Vaillant, Geraldine Hipp, Manon Gantenbein, Rejko Krueger, Nico J Diederich
    Frontiers in Neurology.2020;[Epub]     CrossRef

JMD : Journal of Movement Disorders Twitter